Thiry, Etienne ; Université de Liège - ULiège > Département des maladies infectieuses et parasitaires > Virologie, épidémiologie et pathologie des maladies virales
Language :
French
Title :
Les adénovirus recombinants comme vecteurs vaccinaux
ADAM M., OUALIKENE W., LE C.H., GUITTET M., ELOIT M. Replication-defective adenovirus type 5 as an in vitro and in vivo gene transfer vector in chickens. J. Gen. Virol., 1995, 76, 3153-3157.
AIELLO L., GUILFOYLE R., HUEBNER K., WEINMANN R. Adenovirus 5 DNA sequences present and RNA sequences transcribed in transformed human embryo kidney cells (HEK-Ad-5 or 293). Virology, 1979, 94, 460-469.
AKUSIARVI G. Proteins with transcription regulatory properties encoded by human adenoviruses. Trends in Microbiology, 1993, 1, 5, 163-170.
ALDASY P., CSONTOS L., BARTHA A. Pneumo-enteritis in calves caused by adenovirus. Acta Vet. Acad. Sci. Hung., 1965, 15, 167-175.
AMALFITANO A., HAUSER M.A., HU H., SERRA D., BEGY C.R., CHAMBERLAIN J.S. Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted. J. Virol., 1998, 72, 926-933.
BALLAY A., LEVRERO M., TIOLLAIS P., PERRICAUDET M. In Hepadnaviruses. U.C.L.A. symposia on molecular and cellular biology. New series, 1987, vol.70: 481-493. W. Robinson, Koike K., Will H. Editors. New York: Alan R. Liss.
BERK A.J., LEE F., HARRISON T., WILLIAMS J., SHARP P.A. Pre-early adenovirus 5 gene product regulates synthesis of early viral messenger RNAs. Cell, 1979, 17, 935-944.
CALLEBAUT P., ENJUANES L., PENSAERT M. An adenovirus recombinant expressing the spike glycoprotein of porcine respiratory coronavirus is immunogenic in swine. J. Gen. Virol., 1996, 77, 309-313.
CHARLTON K.M., ARTOIS M., PREVEC L., CAMPBELL J.B., CASEY G.A., WELER A.I., ARMSTRONG J. Oral rabies vaccination of skunks and foxes with a recombinant human adenovirus vaccine. Arch. Virol., 1992, 123, 169-179.
CHARTIER C., DEGRYSE E., GANTZER M., DIETERLE A., PAVIRANI A., METHALI M. Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coll, J. Virol., 1996, 70, 4805-4810.
CHENGALVALA M.V, BHAT B.M., BHAT R., LUBECK M.D., MIZUTANI S., DAVIS A.R., HUNG P.P. Immunogenicity of high expression adenovirus-hepatitis B virus recombinant vaccines in dogs. J. Gen. Virol., 1994, 75, 125-131.
CHENGALVALA M.V., BHAT B.M., BHAT R.A., DHEER S.K., LUBECK M.D., PURCELL R.H., MURTHY K.K. Replication and immunogenicity of Ad7-, Ad4-, and Ad5-hepatitis B virus surface antigen recombinants, with or without a portion of E3 region, in chimpanzees. Vaccine, 1997, 15, 335-3159.
CHOW L.T., GELIANAS R.E., BROKER T.R., ROBERTS R.J. An amazing sequence arrangement at the 5+ ends of adenovirus 2 messenger RNA. Cell, 12, 1-8.
CROUZET J., NAUDIN L., ORSINI C., VIGNE E., FERRERO L., LE ROUX A., BENOIT P., LATTA M., TORRENT C., BRANELLEC D., DENEFLE P., MAYAUX J.E., PERRICAUDET M., YEH P. Recombinational construction in Escherichia coli of infectious adenoviral genomes. Proc. Natl. Acad. Sci. U.S.A., 1997, 94, 1414-1419.
ELOIT M., GILARDI-HEBENSTREIT P., TOMA B., PERRICAUDET M. Construction of a defective adenovirus vector expressing the pseudorabies virus glycoprotein gp50 and its use as a live vaccine. J. Gen. Virol., 1990, 71, 2425-2431.
ELOIT M., ADAM M. Isogenic adenoviruses type 5 expressing or not expressing the E1A gene: efficiency as virus vectors in the vaccination of permissive and non-permissive species. J. Gen., Virol., 1995, 76, 1583-1589.
ELOIT M. Vaccination par des vecteurs adénoviraux. Virologie, 1998, 2, 109-120.
GALLICHAN W.S., JOHNSON D.C., GRAHAM F.L., ROSENTHAL K.L. Mucosal immunity protection after intranasal immunization with recombinart adenovirus expressing herpes simplex virus glycoprotein B. J. Infect. Dis., 1993, 168, 622-629.
GANNE V., ELOIT M., LAVAL A., ADAM M., TROUVE G. Enhancement of the efficacy of a replication-defective adenovirus-vectored vaccine by the addition of oil adjuvants. Vaccine, 1994, 12, 1190-1196.
GAO G.P., YANG Y., WILSON J.M. Biology of adenovirus vectors with E1 E4 deletions for liver-directed gene therapy. J. Virol., 1996, 70, 8934-8943.
GINSBERG H.S., LUNDHOLM-BEAUCHAMP U., HORSWOOD R.L., PERNIS B., WOLD W.S., CHANOCK R.M., PRINCE G.A. Role of early region 3 (E3) in pathogenesis of adenovirus disease. Proc. Natl. Acad. Sci. U.S.A., 1939, 86, 3823-3827.
GONIN P., OUALIKENE W., FOURNIER A., SOULIER M., AUDONNET J-CH., RIVIERE M., ELOIT M. Evaluation of a Replication-Delective Adenovirus Expressing the Feline Infectious Peritonitis Membrane Protein as a Vaccine in Cats. Vaccine Research, 1996, 4, 217-227.
GOODING L.R., ELMORE L.E., TOLLEFSON A.E., BRODY H.A., WOLD W.S.M. A 14,700 MW protein from the E3 region of adenovirus inhibits cytolysis by tumor necrosis factor. Cell, 53, 341-346.
GHOSH-CHOUDHURY G., HAI-AHMED Y., GRAHAM F.L. Protein IX component of the human adenovirus capsid is essential for the packaging of full length genomes. EMBO J., 1987, 6, 1733-1739.
FISHER K.J., CHOI H., BURDA J., CHEN S.J., WILSON J.M. Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis. Virology, 1996, 217, 11-22.
GRAHAM F.L., SMILEY J., RUSSELL W.C., NAIRN R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol., 1977, 36, 59-74.
HEARING P., SHENKT. The adenovirus type 5 E1A transcriptional control region contains a duplicated enhancer element. Cell, 1983, 33, 695-703.
HEARING P., SHENK T. The adenovirus type 5 E1A enhancer contains two fonctionally distincts domains: one is specific for E1A and other modulated all early units en cis.Cell, 1986, 45, 229-236.
HORWITZ M.S. Adenoviridae anc their replication in: Virology 2nd Fields B.N., Knipe D.M., Chanock R.M., Hirsh M.S., Melnick J.L., Monath T.P., Roizman B. ends., Raven Press, New York, 1990a, 1679-1721.
HORWITZ M.S. Adenoviruses in: Virology 2nd Fields B.N., Knipe D.M., Chanock R.M., Hirsh M.S., Melnick J.L., Monath T.P., Roizman B. ends., Raven Press, New York, 1990b, 1723-1740.
HUEBNER R.J., ROWE W.P., WARD T.J., PARROT R.H., BELL J.A. Adenoidal-pharyngal-conjuctival agents. A newly recognized group of common viruses of the respiratory system. N. Engl. J. Med., 1954, 251, 1077-1186.
JOHNSON D.C., GHOSH-CHOUDHURY C., SMILEY J.R., FALLIS L., GRAHAM F.L. Abundant expression of herpes simplex virus glycoprotein gB using an adenovirus vector. Virology, 1988, 164, 1-14.
KLESSIG D.E. GRODZICKER T. Mutations that allow human Ad2 and Ad5 to express late genes in monkey cells map in the viral gene encoding the 72K DNA binding protein. Cell, 1979, 17, 957-966.
KLONIKOWSKI B., GILARDI-HEBENSTREIT P., HADCHOUEL J., RRIANARISON V., BOUTIN S., YEH P., PERRICAUDET M., KREMER E.J. A recombinant E1-deleted canine adenoviral vector capable of transduction expression of a transgene in human-derived cells and in vivo [see comments]. Hum. Gene Ther., 1997, 8, 2103-2115.
LELEU G., LE JUNTER J., MORINET F. Les pneumonies à adénovirus. Annales de l'Institut Pasteur, 1995, 6, 18-22.
LEONG K., LEE W., BERK A.J. High-level transcription from the adenovirus major late promoter requires downstream binding sites for late-phase-specific factors. J. Virol., 1990, 64, 1, 51-60.
LUBECK M.D., DAVIS A.R., CHENGALVALA M., NATUK R.J., MORIN I.E., MOLNAR-KIMBER K., MASON B.B., BHAT B.M., MIZUTANI S., HUNG P.P. Immunogenicity and efficacy testing in chimpanzees of an oral hepatitis B vaccine based on live recombinant adenovirus. Proc. Natl. Acad. Sci. U.S.A., 1989, 86, 6763-6767.
LUBECK M.D., NATUK R.J., CHENGALVALA M., CHA P.K., MURTHY K.K., MURTHY S., MIZUTANI S.. LEE S.G., WADE M.S., BHAT B.M. Immunogenicity of recombinant adenovirus-human immunodeficiency virus vaccines in chimpanzees following intranasal administration AIDS Res. Hum. Retroviruses, 1994, 10, 1443-1449.
LUSKY M., CHRIST M., RITTNER K., DIETERLE A., DREYER D., MOUROT B., SCHULTZ H., STOECKEL F., PAVIRANI A., MEHTALI M. In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted. J. Virol., 1998, 72, 2022-2032.
MASON B.B., DAVIS A.R., BHAT B.M., CHENGALVALA M., LUBECK M.D., ZLE G., KOSTEK B., CHOLODOESKY S., DHEER S., MOLNAR-KIMBER K. Adenovirus vaccine vectors expressing hepatitis B surface antigen: importance of regulatory elements in the adenovirus major late intron. Virology, 1990, 177, 452-461.
MICHOU A.I., SANTORO L., CHRIST M., JULLIARD V., PAVIRANI A., MEHTALI M. Adenovirus-mediated gene transfer: influence of transgene, mouse strain and type of immune response on persistence of transgene expression. Gene Ther., 1997, 4, 473-482.
MITTAL S.K., PREVEC L., GRAHAM F.L., BABIUK L.A. Development of a bovine adenovirus type 3-based expression vector. J. Gen. Virol., 1995, 76, 93-102.
MITTAL S.K., PAPP Z., TIKOO S.K., BACA-ESTRADA M.E., YOO D., BENKO M., BABIUK L.A. Induction of systemic and mucosal immune responses in cotton rats immunized with human adenovirus type 5 recombinants expressing the full and truncated forms of bovine herpesvirus type 1 glycoprotein gD. Virology, 1996, 222, 299-309.
MORIN J.E., LUBECK M.D., BARTON I.E., CONLEY A.J., DAVIS A.R., HUNG P.P. Recombinant adenovirus induces antibody response to hepatitis B virus surface antigene in hamsters. Proc. Natl. Acad. Sci. U.S A., 1987, 84, 4626-4630.
MULLBACHER A. Viral escape from immune recognition: Multiple strategies of adenoviruses. Immunol. Cell Biol., 1992, 70, 59-63.
PAPP Z., BABIUK L.A., BACA-ESTRADA M.E. Induction of immunity in the respiratory tract and protection from bovine herpesvirus type 1 infection by different routes of immunization with recombinant adenovirus. Viral. Immunol., 1998, 11, 79-91.
PARKS R.J., GRAHAM F.L. A helper-dependent system for adenovirus vector production helps define a lower limit for efficient DNA packaging. J. Virol., 1997, 71, 3293-3298.
PERSSON H., SIGMAS C., PHILIPSON C. Purification and characterization of an early glycoprotein from Ad2 infected cells. J. Virology, 1979, 29, 938-948.
POTIER M.F., MONTEIL M., HOUDAYER C., ELOIT M. Study of the delivery of the gD gene of pseudorabies virus to one-day- old piglets by adenovirus or plasmid DNA as ways to by-pass the inhibition of immune response by colostral antibodies. Vet. Microbiol., 1997, 55, 75-80.
PREVEC L., SCHNEIDER M., ROSENTHAL K.L., BELBECK L.W., DERBYSHIRE J.B., GRAHAM F.L. Use of human adenovirus-based vectors for antigen expression in animals. J. Gen. Virol., 1989, 70, 429-434.
RAGOT T., FINERTY S., WATKINS P.E., PERRICAUDET M., MORGAN A.J. Replication-defective recombinant adenovirus expressing the Epstein- Barr virus (EBV) envelope glycoprotein gp340/220 induces protective immunity against EBV-induced lymphomas in the cottontop tamarin. J. Gen. Virol., 1993, 74, 501-507.
RANDRIANARISON-JEWTOUKOFF V., PERRICAUDET M. Recombinant adenoviruses as vaccines. Biologicals, 1995, 23, 145-157.
REDDY P.S., IDAMAKANTI N., HYUN B.H., TIKOO S.K., BABIUK L.A. Development of porcine adenovirus-3 as an expression vector. J. Gen. Virol., 1999, 80, 563-570.
REICH P.R., ROSE J., LEVINE A. RNA of low molecular weight in KB cells infected with Ad2. J. Mol. Biol., 1966, 17, 428-439.
ROTHEL J.S., BOYLE D.B., BOTH G.W., PYE A.D., WATERKEYN J.G., WOOD P.R., LIGHTOWLERS M.W. Sequential nucleic acid and recombinant adenovirus vaccination induces host-protective immune responses against Taenia ovis infection in sheep. Parasite Immunol., 1997, 19, 221-227.
ROUTES J.M., BELLGRAU D., MCGRORY W.J., BAUTISTA D.S., GRAHAM F.L., COOK J.L. Anti-adenovirus type 5 cytotoxic T lymphocytes: immunodominant epitopes are encoded by the E1A gene. J. Virol., 1991, 65, 1450-1457.
RUBARTH S. An acute virus disease with liver lesion in dogs (hepatitis contagiosa canis). A pathologicoanatomical and etiological invastigation. Acta pathologica et microbiologica scandinavica, 1947, 69, 222.
SCHNEIDER M., GRAHAM F.L., PREVEC L. Expression of the glycoprotein of vesicular stomatitis virus by infectious adenovirus vectors. J. Gen. Virol., 1989, 70, 417-427.
SHENK T. Adenoviridae: The viruses and their replication In Fields B.N., Knipe D.M., Howley P.M. (ed.), Fields Virology, third edition. Lippencott Raven Press, New York, 1996, 2111-2137.
THIMMAPPAYA B., WEINBERGER C., SCHEINDER R.J., SHENK T. Adenovirus VAI RNA is required for efficient translation of viral mRNAs at late times after infection. Cell, 1982, 31, 543-551.
TOOZE J. DNA tumor viruses: molecular biology of tumor viruses, 2nd edition. Cold Spring Harbor, New York: Cold Spring Harbor Labaratory, 1981, 937-1036.
VAN DER VLIET P.C., SUSSENBACH J.S. An adenovirus type 5 gene function required for initiation of viral DNA replication. Virology, 1975, 67, 415-426.
WOLD W.S., GOODING L.R. Region E3 of adenovirus: a cassette of genes involved in host immunosurveillance and virus-cell interactions. Virology, 1991, 184, 1-8.
XIANG Z.Q., YANG Y., WILSON J.M., ERTL H.C. A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. Virology, 1996, 219, 220-227.
YAROSH O.K., WELER A.I., GRAHAM F.L., CAMPBELL J.B., PREVEC L. Human adenovirus type 5 vectors expressing rabies glycoprotein. Vaccine, 1996, 14, 1257-1264.
YE W.W., MASON B.B., CHENGALVALA M., CHENG S.M., ZLE G., LUBECK M.D., LEE S.G., MIZUTANI S., DAVIS A.R., HUNG P.P. Co-expression of hepatitis B virus antigens by a non-defective adenovirus vaccine vector. Arch. Virol., 1991, 118, 11-27.
YEH P., DEDIEU J.F., ORSINI C., VIGNE E., DENEFLE P., PERRICAUDET M. Efficient dual transcomplementation of adenovirus E1 E4 regions from a 293-derived cell line expressing a minimal E4 functional unit. J. Virol., 1996, 70, 559-565.
ZAKHARTCHOUK A.N., REDDY P.S., BAXI M., BACA-ESTRADA M.E., MEHTALI M., BABIUK L.A., TIKOO S.K. Construction and characterization of E3-deleted bovine adenovirus type 3 expressing full-length and truncated form of bovine herpesvirus type 1 glycoprotein gD. Virology, 1998, 250, 220-229.
ZHENG B., GRAHAM F.L., JOHNSON D.C., HANKE T., MCDERMOTT M.R., PREVEC L. Immunogenicity in mice of tandem repeats of an epitope from herpes simplex gD protein when expressed by recombinant adenovirus vectors. Vaccine, 1993, 11, 1191-1198.
